Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Frances M Richards"'
Autor:
Jennifer P Morton, Matthew Wilson, Hannah Buckley, Alwin G Schuller, Richard Goodwin, Kate Williamson, Frances M Richards, Duncan I Jodrell, Saadia A Karim, Simon J Dovedi, Jim Eyles, Vincenzo Graziano, Andreas Dannhorn, Heather Hulme, Sheng Y Lee, Brajesh P Kaistha, Sabita Islam, James E D Thaventhiran, Rebecca Brais
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. It has been suggested that the adenosine pathway contributes to the ability of PDAC to evade the immune system and hence, its resistance to imm
Externí odkaz:
https://doaj.org/article/f9d832bad08344709ee59ce32bb6e960
Autor:
Timothy I. Johnson, Christopher J. Minteer, Daniel Kottmann, Charles R. Dunlop, Sandra Bernaldo de Quirós Fernández, Larissa S. Carnevalli, Yann Wallez, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Publikováno v:
EBioMedicine, Vol 68, Iss , Pp 103396- (2021)
Background: Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle specificities of a number
Externí odkaz:
https://doaj.org/article/4408046a6c6241ba8f27a66d0de90ae8
Autor:
Matthew J. Sale, Emma Minihane, Noel R. Monks, Rebecca Gilley, Frances M. Richards, Kevin P. Schifferli, Courtney L. Andersen, Emma J. Davies, Mario Aladren Vicente, Eiko Ozono, Aleksandra Markovets, Jonathan R. Dry, Lisa Drew, Vikki Flemington, Theresa Proia, Duncan I. Jodrell, Paul D. Smith, Simon J. Cook
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-19 (2019)
BRAF or MEK1/2 inhibitors are cytostatic in melanoma and the surviving cells develop drug resistance. This study shows that the pro-survival pool is biased towards MCL1 in melanoma so that BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1
Externí odkaz:
https://doaj.org/article/03dfbb8e162440b8bfec0b14545e606c
Autor:
Iswarya Ramu, Sören M. Buchholz, Melanie S. Patzak, Robert G. Goetze, Shiv K. Singh, Frances M. Richards, Duncan I. Jodrell, Bence Sipos, Philipp Ströbel, Volker Ellenrieder, Elisabeth Hessmann, Albrecht Neesse
Publikováno v:
EBioMedicine, Vol 48, Iss , Pp 161-168 (2019)
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterised by extensive matrix deposition that has been implicated in impaired drug delivery and therapeutic resistance. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular
Externí odkaz:
https://doaj.org/article/bdd07b0e60bc40a3bd3995e138dddca8
Autor:
Melanie S. Patzak, Vijayalakshmi Kari, Shilpa Patil, Feda H. Hamdan, Robert G. Goetze, Marius Brunner, Jochen Gaedcke, Julia Kitz, Duncan I. Jodrell, Frances M. Richards, Christian Pilarsky, Robert Gruetzmann, Petra Rümmele, Thomas Knösel, Elisabeth Hessmann, Volker Ellenrieder, Steven A. Johnsen, Albrecht Neesse
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 394-405 (2019)
Background: Cytosolic 5′-nucleotidase 1A (NT5C1A) dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates. Here, we investigate NT5C1A expression in pancreatic ductal adenocarcinoma (PDAC) and its impac
Externí odkaz:
https://doaj.org/article/195147ef850549bba1a4da0c7a0248e9
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of PDAC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48842dba68fded585e597a16be131cc3
https://doi.org/10.1158/1535-7163.22504494
https://doi.org/10.1158/1535-7163.22504494
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a674a747e8fbe7b3589a446453eeda2e
https://doi.org/10.1158/1535-7163.c.6537753.v1
https://doi.org/10.1158/1535-7163.c.6537753.v1
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
Genetic alterations likely to sensitize to ATR inhibition in the human PDAC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae5ee54dffa886a110e637a547155f5
https://doi.org/10.1158/1535-7163.22504491
https://doi.org/10.1158/1535-7163.22504491
Autor:
Kairbaan Hodivala-Dilke, Pedro R. Cutillas, Cyrill Géraud, Ping-Pui Wong, Victoria Sanz-Moreno, Dieter Saur, Peter B. Vermeulen, Ya-Ming Meng, Christof Dormann, Céline Weller, Frances M. Richards, Jesús Gómez-Escudero, Rebecca J.G. Drake, Vinothini Rajeeve, Emma Newport, Laura Wisniewski, Oscar Maiques, Beatriz de Luxán-Delgado, Louise E. Reynolds, Marina Roy-Luzarraga
Supplementary Data from Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6fbefb5bd893c63c43ec853b8f0ac9
https://doi.org/10.1158/0008-5472.22430214.v1
https://doi.org/10.1158/0008-5472.22430214.v1
Autor:
Kairbaan Hodivala-Dilke, Pedro R. Cutillas, Cyrill Géraud, Ping-Pui Wong, Victoria Sanz-Moreno, Dieter Saur, Peter B. Vermeulen, Ya-Ming Meng, Christof Dormann, Céline Weller, Frances M. Richards, Jesús Gómez-Escudero, Rebecca J.G. Drake, Vinothini Rajeeve, Emma Newport, Laura Wisniewski, Oscar Maiques, Beatriz de Luxán-Delgado, Louise E. Reynolds, Marina Roy-Luzarraga
Despite substantial advances in the treatment of solid cancers, resistance to therapy remains a major obstacle to prolonged progression-free survival. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a high level of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dda4b98719c7b41db9c381a53b02befb
https://doi.org/10.1158/0008-5472.c.6513567.v1
https://doi.org/10.1158/0008-5472.c.6513567.v1